Literature DB >> 25692807

Liver transplantation in the context of organ shortage: toward extension and restriction of indications considering recent clinical data and ethical framework.

Valerio Lucidi1, Thierry Gustot, Christophe Moreno, Vincent Donckier.   

Abstract

PURPOSE OF REVIEW: The scarcity of liver grafts requires to optimize the results of transplantation. Extensions and alternatives of liver transplantation have to be regularly evaluated. RECENT
FINDINGS: Acute-on-chronic liver failure and severe alcoholic hepatitis may represent potential extensions of transplant indications. In these diseases, selected patients could obtain a significant benefit from liver transplantation, whereas long-term outcomes and global impact on waiting lists remain to be evaluated prospectively. Alternatives to transplantation may be represented by recent progress in the management of hepatitis C and the treatment of hepatocellular carcinoma. In hepatitis C, new drug combinations may improve the disease control, reducing the progression to cirrhosis and also the risk of post-transplant reinfection allowing to anticipate a future decrease in the indications for transplantation and retransplantation in these patients. In hepatocellular carcinoma, thanks to improvements in operative techniques and better identification of prognostic factors of cancer recurrency, surgical resection or radiofrequency destruction could appear now as true alternatives to transplant in highly selected patients.
SUMMARY: Before implementation of these potential changes into decisional algorithms for listing and organ allocation, their consequences, either for patient's individual benefit or for global transplant outcomes, should be closely evaluated using objective long-term end points and taking into account the ethical recommendations for organ transplantation.

Entities:  

Mesh:

Year:  2015        PMID: 25692807     DOI: 10.1097/MCC.0000000000000186

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  5 in total

1.  High-throughput Functional Genomics Identifies Regulators of Primary Human Beta Cell Proliferation.

Authors:  Karine Robitaille; Jillian L Rourke; Joanne E McBane; Accalia Fu; Stephen Baird; Qiujiang Du; Tatsuya Kin; A M James Shapiro; Robert A Screaton
Journal:  J Biol Chem       Date:  2016-01-06       Impact factor: 5.157

2.  Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities.

Authors:  Cyrill Wehling; Michael T Dill; Alexander Olkus; Christoph Springfeld; De-Hua Chang; Patrick Naumann; Thomas Longerich; Clemens Kratochwil; Arianeb Mehrabi; Uta Merle; Jan Pfeiffenberger; Christian Rupp; Karl Heinz Weiss; Markus Mieth
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-04       Impact factor: 4.553

3.  Challenging the principle of utility as a barrier for wider use of liver transplantation for hepatocellular cancer.

Authors:  Michał Grąt; Jan Stypułkowski; Waldemar Patkowski; Karolina M Wronka; Emil Bik; Maciej Krasnodębski; Łukasz Masior; Zbigniew Lewandowski; Michał Wasilewicz; Karolina Grąt; Marek Krawczyk; Krzysztof Zieniewicz
Journal:  Ann Surg Oncol       Date:  2017-07-10       Impact factor: 5.344

4.  Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers.

Authors:  Danny van der Helm; Marieke C Barnhoorn; Eveline S M de Jonge-Muller; Ilse Molendijk; Luuk J A C Hawinkels; Minneke J Coenraad; Bart van Hoek; Hein W Verspaget
Journal:  J Cell Mol Med       Date:  2019-06-27       Impact factor: 5.310

5.  Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis.

Authors:  Sofia Karkampouna; Danny van der Helm; Mario Scarpa; Bart van Hoek; Hein W Verspaget; Marie-Jose Goumans; Minneke J Coenraad; Boudewijn P T Kruithof; Marianna Kruithof-de Julio
Journal:  Cells       Date:  2021-11-26       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.